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Summary  The  traditional  role  of  lipids  in  the  generation  of  lipid-based  supramolecular  struc-
tures has  predominantly  been  to  serve  as  building  blocks  to  support  the  delivery  or  stabilization
of a  molecule  or  structure.  With  an  introduction  to  the  synthesis  of  porphyrin-lipid,  a  por-
phyrin conjugated  to  a  phospholipid,  and  the  discovery  of  porphysome  nanovesicles,  the  role
of phospholipids  in  supramolecular  structures  has  shifted  from  a  simple  support  to  an  intrinsic
imaging and  therapeutic  agent.  Here  we  provide  an  overview  of  recent  developments  in  the
generation of  supramolecular  structures  using  porphyrin-lipid  and  their  applications  in  therapy
and imaging,  including  photothermal  therapy,  photoacoustic  imaging,  multimodality  imaging
and activatable  ﬂuorescence  imaging  and  photodynamic  therapy.  Furthermore,  we  introduce
several new  developments  within  the  ﬁeld  of  using  organic  nanoparticles  for  thermal-based
biomedical  applications  using  other  organic  nanomaterials.
© 2014  Published  by  Elsevier  Ltd.
introductionipid-based  supramolecular  structures  have  been  developed
or  a  number  of  biomedical  applications  in  therapy  and
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748-0132/© 2014 Published by Elsevier Ltd.maging  of  disease  and  have  received  tremendous  clinical
uccess.  In  particular,  liposomes,  spherical  nanoparticles
onsisting  of  a  lipid  bilayer,  have  been  clinically  approved
o  deliver  chemotherapy  drugs,  such  as  doxorubicin  (Doxil®,
anssen  Biotech)  used  to  treat  ovarian  cancer,  breast  can-
er  and  Kaposi’s  sarcoma  [1]. Several  other  drug  loaded
iposomes  have  also  been  approved  or  are  in  clinical  trial
or  various  cancers,  details  of  which  can  be  found  in  the
ollowing  reference  [2]. The  highly  desired  clinical  suc-
ess  of  these  liposomes  has  been  based  on  their  high
n
e
v
m
m
l
b
r
e
i
s
s
n
P
A
r
p
p
i
a
l
a
t
a
h
r
(
m
e
b
g
u
f
p
p
r
(
f
l
h
h
c
u
p
f
t
f
o
t
s
1
aPorphysome  nanotechnology  
biocompatibility,  biodegradation  and  clearance  properties,
in  addition  to  their  high  therapeutic  efﬁcacy  or  contrast
enhancement  capabilities.  The  organic  nature  of  lipids  has
the  ability  to  avoid  eliciting  an  undesired  immune  response
[3]  and  ensure  safe  and  timely  clearance  from  the  body
[4,5].  However,  the  clinical  role  of  the  lipids  themselves  has
been  restricted  as  simple  carriers  used  to  increase  the  circu-
lation  time  of  the  agent  and  prevent  interaction  of  the  agent
with  blood  components.  In  the  case  of  liposomes,  the  lipids
form  a  spherical  compartment  to  carry  the  chemotherapy
drug  to  tumors,  to  decrease  non-speciﬁc  uptake  and  increase
circulation  time.  The  lipids  serve  as  building  blocks  to  form
a  vehicle  to  deliver  the  therapy  or  imaging  agents,  but
they  themselves  are  not  intrinsically  therapeutic  or  imaging
agents.
Porphyrins  are  also  another  group  of  organic  compounds
that  have  received  clinical  success.  Porphyrins  have  been
one  of  the  most  extensively  investigated  molecules  for
biomedical  applications  [6]  including  ﬂuorescence  imag-
ing  [7—11],  magnetic  resonance  imaging  (MRI)  [12,13]  and
nuclear  imaging  [14—16,17].  Porphyrins  are  composed  of
four  pyrrole  subunits  forming  a  22  electron  system,  which
is  the  root  of  their  photophysical  properties.  Porphyrins  also
behave  as  an  intrinsic  metal  chelator  in  which  they  may
possess  a  central  metal  atom,  enabling  their  applications
in  MRI  and  nuclear  medicine.
Furthermore,  most  notably,  porphyrins  have  achieved
clinical  success  as  photosensitizers  in  photodynamic  ther-
apy  (PDT)  for  cancer  and  ophthalmic  diseases  [18—20]. PDT
consists  of  the  administration  of  light  and  a  photosensitizing
agent  in  the  presence  of  oxygen  to  generate  cytotoxic  sin-
glet  oxygen.  Porphyrins’  favorable  photophysical  properties
[21],  including  long  wavelength  absorption  and  high  singlet
oxygen  quantum  yield,  and  low  in  vivo  toxicity  have  all
contributed  to  their  clinical  success  [22,23]. For  example,
benzoporphyrin  derivative  monoacid  (BPD-MA)  derived  from
protoporphyrin  IX  (PpIX)  dimethyl  ester  was  demonstrated
to  be  a  potent  photosensitizer  both  in  vitro  and  in  vivo, and
in  clinical  trials  [24].  However,  as  many  porphyrins  exhibit  a
high  level  of  lipophilicity,  including  BPD-MA,  they  have  a ten-
dency  to  aggregate  in  aqueous  solution,  therefore,  limiting
its  bioavailability  [25].  To  circumvent  this  problem,  por-
phyrins  have  been  incorporated  into  liposomes  for  improved
delivery,  solubility  and  efﬁcacy.
Porphyrin  liposomes
To  improve  the  bioavailability  of  BPD-MA,  and  ensure  that
it  remains  in  its  monomeric  form  upon  intravenous  adminis-
tration,  liposomes  were  used  as  a  delivery  vehicle  carrying
BPD-MA  within  its  bilayer  lipid  membrane  [26].  Liposomal
BPD-MA,  marketed  as  Visudyne® (Valeant  Pharmaceuticals
International,  Inc.),  had  enhanced  tumor  accumulation  and
greater  in  vivo  photosensitizer  potency  over  its  free  form,
which  has  contributed  to  its  clinical  success  and  implemen-
tation  for  age-related  macular  degeneration  [23,26—28].
Visudyne  is  one  example  of  many  porphyrins  that  have
been  incorporated  into  liposomal  nanostructures  in  order
to  improve  its  in  vivo  performance.  A  signiﬁcant  amount
of  work  is  currently  being  dedicated  to  formulation  opti-
mization  and  targeting  of  liposome-based  photosensitizer
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anostructures  to  further  improve  their  PDT  efﬁcacy,
xpanding  their  applications  to  other  indications  including
arious  cancers  [29—32],  dermatologic  diseases  [33—35]  and
icrobial  infections  [36,37].
However,  the  incorporation  of  porphyrins  within  a  liposo-
al  membrane  is  limited  to  only  a  molar  fraction  of  the  total
ipid  amount,  beyond  which  results  in  nanostructure  insta-
ility  [38].  In  speciﬁc  biomedical  applications  which  do  not
equire  high  porphyrin  loading  for  a  signiﬁcant  therapeutic
fﬁcacy  or  imaging  contrast,  such  as  PDT  and  ﬂuorescence
maging,  this  low  loading  capacity  of  the  membrane  is
ufﬁcient  to  produce  the  desired  effects.  However,  this
igniﬁcantly  limits  the  broad  applications  of  these  organic
anoparticles  requiring  greater  porphyrin  content.
orphyrin-lipid  nanostructures
lternative  methods  have  been  investigated  to  incorpo-
ate  porphyrins  into  liposomes  by  direct  conjugation  of  the
orphyrin  to  phospholipids.  Komatsu  et  al.  conjugated  a
orphyrin  to  the  acyl  chain  of  a  phospholipid,  resulting
n  a  4:1  phospholipid:  porphyrin  molecule  ratio  (Fig.  1a),
nd  demonstrated  that  this  construct  could  form  liposome-
ike  structures  with  distinct  photophyiscal  properties  such
s  a  red-shifted  Soret  band,  strong  ﬂuorescence  and  short
riplet  state  lifetime  [39,40].  Riske  et  al.  also  synthesized
 porphyrin-lipid  conjugate  by  attaching  a  porphyrin  to  the
ead  groups  of  two  phospholipids  (referred  to  as  PE-porph),
esulting  in  a  2:1  phospholipid:  porphyrin  molecule  ratio
Fig.  1b)  [41].  They  used  PE-porph  to  form  giant  vesicles,
icron  sized  lipid  bilayer  vesicles,  and  investigated  the
ffect  of  light  irradiation  on  the  shape  of  the  vesicle  induced
y  singlet  oxygen  generation.  Although  a  novel  approach  for
reater  porphyrin  incorporation  into  lipid  based  supramolec-
lar  structures,  the  generated  structures  were  not  applied
or  any  biomedical  application.
Recently,  Lovell  et  al.  synthesized  a  new  type  of
orphyrin-lipid,  which  consisted  of  the  conjugation  of  a
orphyrin  to  the  glycerol  backbone  of  the  phospholipid,
esulting  in  a  1:1  phospholipid:  porphyrin  molecule  ratio
Fig.  1c)  [38,42].  This  porphyrin-lipid  has  the  ability  to
orm  similar  supramolecular  structures  as  regular  phospho-
ipids  due  to  their  amphipathic  property  resulting  from  the
ydrophobicity  of  the  acyl  chain  and  porphyrin,  and  the
ydrophilic  head  group.  However,  Lovell  et  al.  also  dis-
overed  that  dense  concentration  of  porphyrins  provides
nprecedented  photonic  properties  to  these  structures,  not
ossible  with  regular  phospholipids,  unlocking  a  new  plat-
orm  of  organic  lipid-based  structures  for  thermal-based
herapy,  imaging  and  biological  applications.
The  self-assembly  of  this  porphyrin-lipid  enabled  the
ormation  of  liposome-like  structures  composed  completely
f  porphyrin-lipid,  referred  to  as  porphysomes,  achieving
he  highest  porphyrin  loading  reported  for  a  liposomal
tructure  to  date  (Fig.  2a  and  b).  These  porphysomes  were
00  nm  in  diameter  and  remained  stable  in  solution  for
t  least  9  months  [38].  While  porphyrins  are  known  to
nteract  with  light  to  generate  ﬂuorescence  and  singlet
xygen  [43], the  high  packing  density  of  porphyrins  within
hese  nanovesicles  (>80  000  porphyrins  per  porphysome)
xpanded  the  use  of  porphyrins  for  thermal-based  therapy
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Figure  1  Schematic  of  different  porphyrin-lipids.  (A)  4:1  phospholipid:  porphyrin,  with  the  porphyrin  conjugated  to  the  acyl  chain
of four  phospholipids.  Reprinted  with  permission  from  [39].  Copyright  2002  John  Wiley  and  Sons.  (B)  2:1  phospholipid:  porphyrin,  with
the porphyrin  conjugated  to  the  head  group  of  two  phospholipids.  Reprinted  with  permission  from  [41].  Copyright  2009  Elsevier.  (C)
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rom [38].  Copyright  2011  Nature  Publishing  Group.
nd  imaging  applications.  Nanoparticle  photonic-based
herapy  and  imaging  techniques  requiring  heat  generation
ave  been  extensively  investigated  and  predominantly
tilized  inorganic  nanoparticles  [44—49]  since  organic
anoparticles  do  not  strongly  interact  with  light.  How-
ver,  these  techniques  have  not  been  fruitful  clinically,
t
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igure  2  Porphysome  nanovesicles.  (A)  Schematic  of  porphyrin-l
icroscopy image  of  porphysomes.  (C)  Absorbance  spectra  of  diff
hysomes, orange  —  zinc  pyropheophorbide  porphysomes,  blue  —  py
ontaining liposomes,  gold  nanorods  or  porphysomes  and  irradiate
opyright 2011  Nature  Publishing  Group.cerol  backbone  of  the  phospholipid.  Reprinted  with  permission
otentially  due  to  concerns  regarding  long-term  biodegra-
ation  and  in  vivo  clearance  [50].  Porphysomes  offer  a
romising  organic  alternative  to  inorganic  nanoparticles,  as
heir  organic  nature  enables  them  to  be  biodegradable  and
on-toxic  even  at  extremely  high  concentrations  (1  g/kg
njected  dose)  [38,42]  and  yet  efﬁciently  absorb  light  at
ipid  self-assembly  into  porphysome  nanovesicles.  (B)  Electron
erent  types  of  porphysomes  (red  —  bacteriochlorophyll  por-
ropheophorbide  porphysomes).  (D)  Thermal  images  of  solutions
d  with  a  673  nm  laser.  Reprinted  with  permission  from  [38].
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(Porphysome  nanotechnology  
near  infrared  wavelengths  (Fig.  2c),  generating  heat  levels
comparable  to  inorganic  gold  nanoparticles  (Fig.  2d).
Both  photoacoustic  (PA)  imaging  and  photothermal  ther-
apy  (PTT)  are  centered  on  the  production  of  heat.  In  PA
imaging,  an  optical  absorber  transiently  expands  in  response
to  laser  irradiation  due  to  thermoelastic  expansion,  resulting
in  the  generation  and  detection  of  ultrasound  waves.  With
an  extinction  coefﬁcient  comparable  to  inorganic  nanopar-
ticles,  porphysomes  provided  strong  PA  contrast  shown
through  mapping  of  the  lymphatic  system  in  rats  (Fig.  3a).
In  PTT,  light  is  used  to  generate  heat,  in  which  a  nanopar-
ticle  further  enhances  that  heat  production.  Lovell  et  al.
demonstrated  that  porphysomes  were  potent  agents  for  PTT.
Upon  intravenous  injection  in  a  KB  xenograft  model,  mice
given  both  porphysomes  and  laser  treatment  generated  tem-
peratures  up  to  60 ◦C  in  the  tumor  region  (Fig.  3b  and  c).
As  a  result,  they  had  their  tumors  completely  eradicated,
whereas  those  with  only  laser  alone  or  porphysome  alone
treatments  did  not  survive  beyond  1  month  (Fig.  3d  and  e).
Jin  et  al.  went  on  to  further  demonstrate  that  porphysomes
PTT  treatments  could  destroy  both  hyperoxic  and  hypoxic
tumors  [51].  In  addition,  they  validated  that  the  destruction
of  tumors  was  indeed  due  to  photothermal  heating  and  not
a  photodynamic  effect  due  to  the  self-quenching  of  the  por-
phyrin  within  the  porphysome  nanostructure.  When  tumors
were  treated  with  PDT  conditions  using  porphysomes,  no
signiﬁcant  changes  in  tumor  histology  were  observed  or
reduction  in  tumor  volume,  which  was  seen  with  PTT  treat-
ment  conditions  (Fig.  3f).  These  photonic  properties  of
porphysomes  merge  the  advantages  characteristic  of  lipo-
somes  in  their  organic  nature,  with  the  strong  photonic
properties  unique  to  inorganic  nanomaterials,  pushing  for-
ward  these  emerging  biomedical  photonic  applications  for
clinical  translation.
These  thermal-based  photonic  properties  are  a  result
of  the  high  packing  density  of  porphyrins  within  the  por-
physome  nanostructure,  which  causes  ﬂuorescence  and
singlet  oxygen  self-quenching,  resulting  in  the  generation  of
heat,  and  the  elimination  of  ﬂuorescence  and  singlet  oxygen
production.  Therefore,  this  heat  generating  ability  of  por-
physomes  is  highly  structure  dependent  and  the  disruption  of
the  porphysome  structure  restores  ﬂuorescence  and  singlet
oxygen  production.  The  porphysome  nanostructure  could  be
disrupted  either  using  a  detergent,  which  causes  separation
between  porphyrin-lipid  molecules  within  the  nanostruc-
ture,  thereby  reducing  self-quenching  or  in  vivo  via  the
enhanced  permeability  and  retention  effect  or  by  target-
ing  the  porphysome  and  receptor  mediated  endocytosis.  Jin
and  Cui  et  al.  took  advantage  of  this  structure-dependent
self-quenching  property  of  porphysomes  for  activatable  PDT
(Fig.  4a)  [52].  PDT  involves  the  administration  of  a  pho-
tosensitizer  such  as  a  porphyrin,  the  irradiation  of  light
to  excite  that  photosensitizer,  and  the  resulting  genera-
tion  of  cytotoxic  singlet  oxygen.  They  demonstrated  that
by  targeting  the  porphysomes  to  the  folate  receptor,  over-
expressed  in  many  cancer  cell  lines  [53],  upon  uptake  by
KB  cells  (folate  positive  cells),  ﬂuorescence  was  restored
and  singlet-oxygen  produced  to  kill  the  tumor  cells.  Folate-
targeted  porphysomes  were  intravenously  injected  in  KB
xenograft  bearing  mice.  Fluorescence  imaging  was  used  to
guide  the  treatment  protocol  and  indicate  the  time  window
in  which  PDT  treatment  would  be  optimal  as  indicated  by
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he  highest  restoration  of  ﬂuorescence  (Fig.  4b).  After  24  h,
hich  allowed  for  porphysome  uptake  by  cancer  cells  via
eceptor  mediated  endocytosis  and  disruption  of  the  por-
hysome  structure,  mice  were  treated  with  PDT  and  only
hose  that  were  administered  folate-targeted  porphysomes
aw  a  reduction  in  tumor  size.  However,  laser  treatments
nvolving  non-targeted  porphysomes  were  not  able  to  reduce
umor  size  as  they  were  not  as  efﬁciently  internalized
nd  perturbed  to  their  monomeric  porphyrin-lipid  building
locks  (Fig.  4c).  With  the  high  payload  of  porphyrins  being
arried  in  each  porphysome,  porphysomes  were  demon-
trated  to  be  excellent  activatable  PDT  and  ﬂuorescence
maging  agents.  As  the  porphysome  is  100  nm  in  diameter,
he  size  of  the  nanoparticle  may  impede  deep  tumor  pen-
tration.  To  overcome  this  limitation,  Ng  et  al.  designed
ub-40  nm  porphyrin  nanodiscs  using  porphyrin-lipid  in  which
he  porphyrin-lipid  was  constricted  and  stabilized  by  an
mphipathic  helical  protein,  ApoA-1  (Fig.  4d)  [54].  They
urther  went  on  to  demonstrate  the  activatable  proper-
ies  of  this  porphyrin  nanodisc  (ﬂuorescence  and  singlet
xygen  production  (Fig.  4e  and  f)  upon  disruption  of  the
ompact  structure  and  uptake  via  the  SRB1  receptor,  sug-
esting  potential  applications  for  photosensitizer  delivery
nto  poorly  permeable  tumors.
The  multifunctional  capabilities  of  porphysomes  dis-
ussed  thus  far  have  been  predominantly  based  on  photonic
roperties.  However,  the  intrinsic  ability  of  the  porphyrin
pyropheophorbide-a)  to  chelate  metals  provides  another
pportunity  to  exploit  the  high  porphyrin  content  achieved
ith  porphysomes  and  expands  the  utility  of  porphysomes
o  whole  body  imaging.  Liu  and  MacDonald  et  al.  demon-
trated  that  not  only  could  porphysomes  be  radiolabeled
ith  copper-64  for  PET,  achieve  a  radiolabeling  capacity
reater  than  any  nanoparticle  reported  to  date  (speciﬁc
ctivity  of  2800  Ci/mol  per  nanoparticle),  but  also  do
o  with  a  simple  and  robust  method,  promising  for  the
linical  translation  of  such  a  technology.  Furthermore, 64Cu
helation  to  the  porphyrin  was  shown  to  be  stable  in  serum
or  at  least  24  h  and  was  chemically  stable  in  vivo  for  at
east  30  h,  allowing  PET  to  accurately  track  the  fate  of
orphysomes,  not  the  cleaved  chelator  [55].  Porphysomes
ould  be  preformed,  shipped  to  the  user,  and  radiolabeled
n  site  prior  to  administration,  as  the  radioisotope  inserts
irectly  into  the  porphyrin  building  blocks  of  the  nanoparti-
le.  They  further  explored  the  multifunctional  properties  of
adiolabeled  porphysomes  as  a  dual  imaging  agent  for  PET
nd  ﬂuorescence  imaging  in  an  orthotopic  prostate  cancer
odel  (Fig.  5a)  [56].  Radiolabeled  porphysomes  were  able
o  clearly  distinguish  the  prostate  tumor  from  surrounding
rgans  including  the  bladder  and  prostate  using  both  PET  and
uorescence  imaging  (Fig.  5b  and  c).  This  suggests  the  use
f  radiolabeled  porphysomes  for  prostatectomy,  in  which
ET  would  be  used  for  treatment  planning  and  ﬂuorescence
ould  guide  the  surgical  resection.  Furthermore,  radiola-
eled  porphysomes  were  able  to  identify  small  prostate
ancer  bone  metastases  (<2  mm),  offering  the  potential
o  monitor  tumor  recurrence  and  response  to  treatment
Fig.  5d).  This  ﬁrst  demonstration  of  metal-inserted  por-
hysomes  provides  a  glimpse  of  the  multifaceted  potential
f  porphysomes  for  the  insertion  of  other  metals  such
s  manganese  for  MRI  or  indium-111  for  single  photon
mission  computed  tomography.  The  use  of  metal-inserted
216  E.  Huynh,  G.  Zheng
Figure  3  Thermal-based  photonic  applications  of  porphysomes.  (A)  Photoacoustic  images  of  rat  lymphatic  system  before  and
after the  administration  of  porphysomes  (red  —  lymph  node,  cyan  —  secondary  lymph  vessel,  yellow  —  inﬂowing  lymph  vessel).
(B) Thermal  image  of  mice  bearing  tumor  xenografts  after  being  intravenously  administered  porphysomes  or  PBS  and  irradiated
with a  laser  for  photothermal  therapy  (PTT).  (C)  Quantiﬁcation  of  increase  in  temperature  in  mice  from  (A).  (D)  Resulting  tumor
response after  PTT  treatment.  (E)  Survival  curve  of  mice  receiving  PTT.  Reprinted  with  permission  from  [38].  Copyright  2011  Nature
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orphyrin-lipid  could  also  have  an  indirect  role  in  contrast
nhanced  imaging.  Tam  et  al.  used  manganese-inserted
orphyrin-lipid  to  encapsulate  gold  nanoparticles  for  surface
nhanced  Raman  scattering  (SERS)  based  imaging  [57].  The
anganese  quenched  the  intrinsic  porphyrin  ﬂuorescence,
llowing  the  porphyrin  to  behave  as  a  Raman  dye  without
he  interference  of  ﬂuorescence.  Manganese  porphyrin-
ipid  served  as  both  the  Raman  dye  and  stabilizing  surface
oating,  in  a  single  building  block,  reducing  the  complexity
ften  necessary  of  such  a  nanostructure  for  SERS  imaging.
m
q
F
pxic  and  hypoxic  tumors.  Reprinted  with  permission  from  [51].
While  the  inclusion  of  the  porphyrin  into  the  liposome-
ike  construct  of  porphysomes  provides  inherent  multi-
imensional  photonic  and  other  imaging  properties  for
iagnosis,  image-guidance  and  therapy,  porphysomes  also
aintain  their  liposome-like  nature.  Porphysomes  have  the
bility  to  be  both  passively  and  actively  loaded  with  small
olecules  such  as  doxorubicin,  a  chemotherapy  agent  in
uantities  comparable  to  liposomes  used  clinically  [38].
urthermore,  due  to  the  organic  nature  of  the  single  com-
onent  forming  porphysomes,  porphyrin-lipid,  porphysomes
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Figure  4  Activatable  photonic  applications  of  porphysomes  and  porphyrin  nanodiscs.  (A)  Schematic  of  porphysomes  for  activatable
photodynamic  therapy  (PDT)  and  ﬂuorescence  imaging.  (B)  Fluorescence  images  of  non-targeted  porphysomes  and  folate-targeted
porphysomes  in  KB  xenograft  bearing  mice.  (C)  Photographs  of  tumor  response  to  PDT  with  non-targeted  porphysomes  and  folate-
targeted porphysomes.  Reprinted  with  permission  from  [52].  Copyright  2013  Wiley-VCH  Verlag  GmbH  &  Co.  KGaA,  Weinheim.
(D) Schematic  of  porphyrin  nanodiscs  (inset:  electron  microscopy  image  of  porphyrin  nanodiscs).  (E)  Confocal  images  of  in  vitro
ﬂuorescence activation  upon  internalization  of  porphyrin  nanodiscs.  (F)  Singlet  oxygen  production  upon  disruption  of  porphyrin
ed  w
p
q
r
s
i
B
pnanodiscs detected  using  singlet  oxygen  sensor  green.  Reprint
Society.
are  both  biocompatible,  biodegradable  and  non-toxic,
thereby  incorporating  the  advantages  of  lipid-based  organic
nanoparticles  with  photonic  inorganic  nanoparticles.  While
the  many  avenues  of  porphysome  nanotechnology  are  still
being  currently  explored  (Fig.  6),  we  believe  that  simplistic
multifunctional  nature  of  porphysomes  has  the  potential  to
overcome  several  of  the  clinical  translation  hurdles  preven-
ting  many  nanoparticles  from  proceeding  into  the  clinic.
Based  upon  a  similar  concept  of  porphysomes,  Liang  et  al.
developed  porphyrin-organoalkoxysilylated  lipids  (PORSILs)
with  two  triethoxysilyl  groups,  a  hydrophobic  double-chain
segment,  a  porphyrin,  and  a  connecting  unit  [58]. These
porphyrin  bilayer  cerasomes  carried  a  maximal  porphyrin
B
o
Dith  permission  from  [54].  Copyright  2013  American  Chemical
ayload  while  avoiding  ﬂuorescence  and  singlet  oxygen  self-
uenching  due  to  the  presence  of  the  two  alkyl  chains.  As  a
esult,  they  were  demonstrated  to  be  potent  PDT  agents  and
uggested  to  also  be  a  powerful  tool  for  in  vivo  ﬂuorescence
maging.
eyond  porphyrin  nanoparticles:  micron-sized
orphyrin-lipid  architectureseyond  liposomes  for  drug  delivery,  microbubbles  composed
f  a  lipid  monolayer  shell  encapsulating  a  gas,  such  as
eﬁnity® (Lantheus  Medical  Imaging),  have  been  clinically
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Figure  5  Multimodality  positron  emission  tomography  (PET)  and  ﬂuorescence  imaging  using  porphysomes.  (A)  Schematic  of  a
multimodal  porphysome.  (B)  PET  image  of  radiolabeled  copper-64  porphysomes  injected  intravenously  in  an  orthotopic  prostate
cancer model,  with  the  ability  to  delineate  the  prostate  tumor  (white  arrow).  Reprinted  with  permission  from  [55].  Copyright
2012 Wiley-VCH  Verlag  GmbH  &  Co.  KGaA,Weinheim.  (C)  White  light  (i)  and  ﬂuorescence  image  (ii)  of  copper-64  porphysomes  in
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Sn orthotopic  prostate  cancer  model.  (D)  PET  images  of  prost
opper-64 porphysomes  in  a  healthy  mouse  (ii).  Reprinted  with
pproved  as  ultrasound  contrast  agents  for  several  applica-
ions  including  cardiac  and  liver  imaging  [59,60].  The  gener-
tion  of  new  supramolecular  structures  with  unprecedented
roperties  and  applications  has  not  been  restricted  to  solely
anoparticles.  Porphyrin-lipid  was  used  to  form  microbub-
les  with  a  shell  of  porphyrin  encapsulating  a  ﬂuorinated  gas
Fig.  7a)  [61].  The  presence  of  porphyrin-lipid  imparted  PA
roperties  to  the  microbubble  to  yield  an  intrinsically  dual
odal  US  and  PA  microbubble  (Fig.  7b  and  c).  These  dual
odal  microbubbles  have  promise  for  applying  the  unique
roperties  of  microbubbles,  such  as  microbubble  bursting
o  deliver  drugs  [63],  to  optical  imaging  agents,  potentially
vercoming  resolution  limitations  associated  with  US.
a
v
p
o
igure  6  Multifunctional  properties  of  porphysomes.  Reprinted  w
ociety.ancer  boney  metastases  using  copper-64  porphysomes  (i)  and
ission  from  [56].  Copyright  2013  American  Chemical  Society.
Furthermore,  the  applications  of  porphyrin-lipid  also
xtend  beyond  biomedical  therapeutic  and  imaging  appli-
ations.  Artiﬁcial  micron-size  phospholipid  compartments,
lso  known  as  giant  vesicles,  are  often  used  as  model  cell
embranes  to  study  the  biological  origins  of  life  or  as
icroreactors  due  to  their  picoliter  volume  [64].  In  all  such
pplications,  there  requires  a  means  of  entry  to  load  cargo
nto  these  giant  vesicles.  We  recently  introduced  the  con-
ept  of  using  porphyrin-lipid  and  precise  laser  irradiation  to
ccomplish  this  [62].  Porphyrin-lipid  was  used  to  form  giant
esicles  that  responded  to  a  focused  laser  beam  by  forming
ores  within  the  membrane,  allowing  cargo  to  diffuse  in  and
ut  of  the  vesicle.  Furthermore,  varying  the  laser  ﬂuence
ith  permission  from  [56].  Copyright  2013  American  Chemical
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Figure  7  Porphyrin-lipid  microparticles.  (A)  Schematic  of  porphyrin  shell  microbubbles  (‘porshe’  microbubbles).  (B)  Ultrasound
image of  porphyrin  shell  microbubbles  in  a  breast  cancer  xenograft  bearing  mouse.  Contrast  mode  showing  microbubble  circulation,
inset: (B)-mode  showing  soft  tissue  contrast.  (C)  Photoacoustic  images  of  porphyrin  shell  microbubbles  in  solution.  Reprinted  with
permission from  [61].  Copyright  2012  American  Chemical  Society.  (D)  DNA  hybridization  experiment  in  giant  porphyrin  vesicles.
Opening indicates  laser  irradiation  to  form  a  pore  in  the  membrane.  (E)  Avidin—biotin  experiment  in  giant  porphyrin  vesicles  in
in  to
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nwhich each  laser  irradiation  allowed  binding  of  ﬂuorescent  avid
Reprinted with  permission  from  [62].  Copyright  2013  Wiley-VCH
could  readily  control  the  pore  size.  These  pores  proceeded
to  reseal,  allowing  for  multiple  pore-formation  events.  DNA
hybridization  (Fig.  7d)  and  avidin—biotin  reactions  (Fig.  7e)
were  demonstrated  within  these  giant  porphyrin  vesicles  as
examples  for  potential  applications  of  this  technology  as  a
microreactor.
Other  biophotonic  organic  nanoparticles
Since  the  discovery  of  porphysomes  as  an  organic  nanopar-
ticle  with  optical  extinction  coefﬁcients  similar  to  inorganic
nanoparticles  and  therefore  with  the  ability  to  generate  high
levels  of  heat,  a  number  of  other  highly  absorbing  organic
biophotonic  nanoparticles  have  also  been  developed.  In
particular,  several  organic  biophotonic  nanoparticles  have
been  created  using  conductive  polymers  with  peak  optical
e
d
i
p the  inner  membrane  of  the  vesicle.  10  m  scale  bars  shown.
ag  GmbH  &  Co.  KGaA,  Weinheim.
bsorption  bands  in  the  near  infrared  region.  Polypyr-
ole  is  an  organic  conductive  polymer  used  frequently  in
lectronics  [65,66].  Yang  et  al.  [67]  and  Chen  et  al.  [68]
xtended  its  use  to  biomedical  applications  by  developing
olypyrrole-based  nanoparticles  as  PTT  agents,  increasing
ocal  temperatures  up  to  60 ◦C  in  conjunction  with  laser
rradiation,  and  Zha  et  al.  [69]  went  on  to  further  utilize
hese  polypyrrole  nanoparticles  for  PA  imaging.  In  addition,
olyaniline  was  also  used  to  generate  nanoparticles  that
ould  ablate  cancer  cells  via  PTT  [70].
Furthermore,  the  concept  of  developing  organic
anoparticles  as  PA  contrast  agents  has  continued  to
xpand  beyond  accumulation-based  contrast  agents,  to  the
evelopment  of  organic  activatable  PA  probes  for  molecular
maging  and  sensing.  Pu  et  al.  [71]  created  semiconducting
olymeric  (SP)  nanoparticles  (Fig.  8a)  which  generated
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Figure  8  Semiconducting  polymeric  (SP)  nanoparticles.  (A)  Schematic  of  SP  nanoparticles.  (B)  PA  imaging  of  mass  equivalent
SP nanoparticles,  single-walled  carbon  nanotubes  (SWNT)  and  gold  nanorods  (GNR)  in  a  matrigel  injected  in  vivo.  (C)  ROS  sensing
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Aechanism. (D)  PA  images  of  SP  nanoparticles  in  an  acute  ede
unction of  time  after  zymosan  injection.  Reprinted  with  permi
reater  PA  contrast  than  gold  nanorods  and  single-walled
arbon  nanotubes  (standard  PA  contrast  agents)  per  mass
Fig.  8b).  They  went  on  to  use  these  SP  nanoparticles  for  PA
maging  of  the  detection  of  reactive  oxygen  species  (ROS)  by
bserving  a  decrease  in  PA  signal  at  820  nm  in  the  presence
f  ROS  with  PA  signal  at  700  nm  remaining  constant.  By
sing  a  ratiometric  measure  of  the  PA  signal  at  820  nm  and
00  nm  (Fig.  8c),  they  were  able  to  detect  ROS  generation
n  vivo  using  an  acute  edema  mouse  model.  Zymosan  was
njected  intramuscularly  into  mice,  which  generates  ROS
72],  followed  by  the  injection  of  SP  nanoparticles.  An
ncrease  in  the  ratiometric  PA  measure  using  these  SP
anoparticles  indicated  the  presence  of  ROS  whereas  mice
ithout  zymosan  injection  did  not  experience  an  increase  in
atiometric  PA  signal  (Fig.  8d  and  e)  [71].  With  the  increas-
ng  number  of  highly  absorbing,  heat  producing  organic
iophotonic  nanoparticles  being  reported,  it  is  believed
hat  these  organic  based  nanoparticles  are  the  key  to
ropel  these  photonic  imaging  and  therapy  applications  into
he  clinic.onclusion
hrough  highlighting  these  various  studies,  we  have  shown
hat  the  role  of  a  phospholipid  can  be  radically  changed
T
E
t
Iouse  model.  (E)  Ratiometric  quantiﬁcation  of  PA  values  as  a
 from  [71].  Copyright  2014  Nature  Publishing  Group.
y  the  simple  conjugation  of  a  porphyrin.  The  discovery
f  porphyrin-lipid  has  enabled  photonic  and  activatable
roperties  to  these  supramolecular  structures  for  multi-
odal  imaging,  therapeutic  activity  and  even  biological
pplications.  Furthermore,  the  discovery  of  these  highly
bsorbing  porphysome  nanoparticles  has  opened  a  new  plat-
orm  of  organic  nanoparticles  for  thermal-based  biophotonic
pplications  in  which  we  have  begun  to  observe  several
ther  emerging  organic  nanoparticles  being  reported.  We
elieve  the  clinical  translation  hurdles  to  be  much  lower  for
orphyrin-lipid  supramolecular  structures,  as  a  result  of  the
implicity  of  the  nanostructure,  organic,  biodegradable  and
on-toxic  characteristics  and  the  multidimensional  intrin-
ic  properties  of  the  porphyrin-lipid  and  its  self-assembled
anostructures.  The  generation  of  porphyrin-lipid  based
upramolecular  structures  has  broad  implications  for  clin-
cal  translation  to  overcome  a  vast  array  of  imaging  and
herapeutic  barriers.
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